Pfizer Income from Discontinued Operations 2012-2026 | PFE
Pfizer annual/quarterly income from discontinued operations history and growth rate from 2012 to 2026. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
- Pfizer income from discontinued operations for the quarter ending March 31, 2026 was $-13M, a 0% increase year-over-year.
- Pfizer income from discontinued operations for the twelve months ending March 31, 2026 was $12M, a 25% decline year-over-year.
- Pfizer annual income from discontinued operations for 2025 was $0.025B, a 127.27% increase from 2024.
- Pfizer annual income from discontinued operations for 2024 was $0.011B, a 173.33% decline from 2023.
- Pfizer annual income from discontinued operations for 2023 was $-0.015B, a 350% decline from 2022.
|
Pfizer Annual Income from Discontinued Operations (Millions of US $) |
|
|---|---|
| 2025 | $25 |
| 2024 | $11 |
| 2023 | $-15 |
| 2022 | $6 |
| 2021 | $-434 |
| 2020 | $2,529 |
| 2019 | $5,318 |
| 2018 | $7,328 |
| 2017 | $2 |
| 2016 | $16 |
| 2015 | $11 |
| 2014 | $48 |
| 2013 | $10,662 |
| 2012 | $5,577 |
| 2011 | $2,189 |
|
Pfizer Quarterly Income from Discontinued Operations (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-13 |
| 2025-12-31 | |
| 2025-09-30 | $0 |
| 2025-06-30 | $25 |
| 2025-03-31 | $0 |
| 2024-12-31 | $7 |
| 2024-09-30 | $-8 |
| 2024-06-30 | $17 |
| 2024-03-31 | $-5 |
| 2023-12-31 | $-26 |
| 2023-09-30 | $12 |
| 2023-06-30 | $-2 |
| 2023-03-31 | $1 |
| 2022-12-31 | $2 |
| 2022-09-30 | $-21 |
| 2022-06-30 | $34 |
| 2022-03-31 | $-9 |
| 2021-12-31 | $-186 |
| 2021-09-30 | $-13 |
| 2021-06-30 | $-236 |
| 2021-03-31 | $1 |
| 2020-12-31 | $195 |
| 2020-09-30 | $560 |
| 2020-06-30 | $893 |
| 2020-03-31 | $881 |
| 2019-12-31 | $5,314 |
| 2019-09-30 | $4 |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | $7,318 |
| 2018-09-30 | $11 |
| 2018-06-30 | |
| 2018-03-31 | $-1 |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | $2 |
| 2017-03-31 | |
| 2016-12-31 | $15 |
| 2016-09-30 | |
| 2016-06-30 | $1 |
| 2016-03-31 | |
| 2015-12-31 | $-3 |
| 2015-09-30 | $8 |
| 2015-06-30 | $1 |
| 2015-03-31 | $5 |
| 2014-12-31 | $-22 |
| 2014-09-30 | $-3 |
| 2014-06-30 | |
| 2014-03-31 | $73 |
| 2013-12-31 | $-57 |
| 2013-09-30 | $11 |
| 2013-06-30 | $10,559 |
| 2013-03-31 | $149 |
| 2012-12-31 | $5,013 |
| 2012-09-30 | $225 |
| 2012-06-30 | $260 |
| 2012-03-31 | $79 |
| 2011-12-31 | $658 |
| 2011-09-30 | $1,424 |
| 2011-06-30 | $97 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |